HOE MEER TIGENIX IN DE KIJKER KOMT, HOE BETER:
BIOWORLD
Tigenix gets EMA nod for off-the-shelf stem cell therapy in Crohn's disease
Share
By Nuala Moran
Staff Writer
Monday, December 18, 2017
Buy Reprint
LONDON - Eight years on from securing the first EMA approval for an autologous cell therapy, Tigenix NV has done it again, getting the nod for the first allogeneic adipose-derived stem cell therapy, Alofisel (Cx601, darvadstrocel), in the treatment of complex anal fistulas caused by Crohn's disease.